These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

460 related items for PubMed ID: 16128674

  • 1. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation.
    Reilly MC, Barghout V, McBurney CR, Niecko TE.
    Aliment Pharmacol Ther; 2005 Sep 01; 22(5):373-80. PubMed ID: 16128674
    [Abstract] [Full Text] [Related]

  • 2. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
    Harish K, Hazeena K, Thomas V, Kumar S, Jose T, Narayanan P.
    J Gastroenterol Hepatol; 2007 Aug 01; 22(8):1183-9. PubMed ID: 17688659
    [Abstract] [Full Text] [Related]

  • 3. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.
    Chey WD, Paré P, Viegas A, Ligozio G, Shetzline MA.
    Am J Gastroenterol; 2008 May 01; 103(5):1217-25. PubMed ID: 18477346
    [Abstract] [Full Text] [Related]

  • 4. The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study.
    Bardhan KD, Forbes A, Marsden CL, Mason T, Short G.
    Aliment Pharmacol Ther; 2004 Jul 15; 20(2):213-22. PubMed ID: 15233702
    [Abstract] [Full Text] [Related]

  • 5. Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation.
    Müller-Lissner S, Holtmann G, Rueegg P, Weidinger G, Löffler H.
    Aliment Pharmacol Ther; 2005 Jan 01; 21(1):11-20. PubMed ID: 15644040
    [Abstract] [Full Text] [Related]

  • 6. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
    Tack J, Müller-Lissner S, Bytzer P, Corinaldesi R, Chang L, Viegas A, Schnekenbuehl S, Dunger-Baldauf C, Rueegg P.
    Gut; 2005 Dec 01; 54(12):1707-13. PubMed ID: 16020489
    [Abstract] [Full Text] [Related]

  • 7. Review article: tegaserod -- the global experience.
    Chey WD.
    Aliment Pharmacol Ther; 2004 Nov 01; 20 Suppl 7():15-9. PubMed ID: 15521850
    [Abstract] [Full Text] [Related]

  • 8. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study.
    Kamm MA, Müller-Lissner S, Talley NJ, Tack J, Boeckxstaens G, Minushkin ON, Kalinin A, Dzieniszewski J, Haeck P, Fordham F, Hugot-Cournez S, Nault B.
    Am J Gastroenterol; 2005 Feb 01; 100(2):362-72. PubMed ID: 15667494
    [Abstract] [Full Text] [Related]

  • 9. Review article: tegaserod for chronic constipation.
    Johanson JF.
    Aliment Pharmacol Ther; 2004 Nov 01; 20 Suppl 7():20-4. PubMed ID: 15521851
    [Abstract] [Full Text] [Related]

  • 10. [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome].
    Tegaserod Clinical Research Group.
    Zhonghua Nei Ke Za Zhi; 2003 Feb 01; 42(2):88-90. PubMed ID: 12783702
    [Abstract] [Full Text] [Related]

  • 11. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome.
    Khoshoo V, Armstead C, Landry L.
    Aliment Pharmacol Ther; 2006 Jan 01; 23(1):191-6. PubMed ID: 16393297
    [Abstract] [Full Text] [Related]

  • 12. The validity and accuracy of the Work Productivity and Activity Impairment questionnaire--irritable bowel syndrome version (WPAI:IBS).
    Reilly MC, Bracco A, Ricci JF, Santoro J, Stevens T.
    Aliment Pharmacol Ther; 2004 Aug 15; 20(4):459-67. PubMed ID: 15298641
    [Abstract] [Full Text] [Related]

  • 13. [Tegaserod in treatment of women with irritable bowel syndrome].
    Munck LK, Ainsworth MA.
    Ugeskr Laeger; 2007 Jun 04; 169(23):2190-2. PubMed ID: 17592683
    [Abstract] [Full Text] [Related]

  • 14. Tegaserod for constipation-predominant irritable bowel syndrome.
    Kale-Pradhan PB, Wilhelm SM.
    Pharmacotherapy; 2007 Feb 04; 27(2):267-77. PubMed ID: 17253916
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of tegaserod in chronic constipation in men.
    Fried M, Johanson JF, Gwee KA, Wagner A, Pecher E, Rueegg P.
    Am J Gastroenterol; 2007 Feb 04; 102(2):362-70. PubMed ID: 17156137
    [Abstract] [Full Text] [Related]

  • 16. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome.
    Nyhlin H, Bang C, Elsborg L, Silvennoinen J, Holme I, Rüegg P, Jones J, Wagner A.
    Scand J Gastroenterol; 2004 Feb 04; 39(2):119-26. PubMed ID: 15000272
    [Abstract] [Full Text] [Related]

  • 17. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P, Dapoigny M, Bonaz B, Siproudhis L.
    Aliment Pharmacol Ther; 2005 Feb 15; 21(4):435-44. PubMed ID: 15709995
    [Abstract] [Full Text] [Related]

  • 18. Review article: the safety profile of tegaserod.
    Schoenfeld P.
    Aliment Pharmacol Ther; 2004 Nov 15; 20 Suppl 7():25-30. PubMed ID: 15521852
    [Abstract] [Full Text] [Related]

  • 19. Tegaserod treatment for IBS: a model of indirect costs.
    Smith DG, Barghout V, Kahler KH.
    Am J Manag Care; 2005 Apr 15; 11(1 Suppl):S43-50. PubMed ID: 15926763
    [Abstract] [Full Text] [Related]

  • 20. Effect of tegaserod on recto-sigmoid tonic and phasic activity in constipation-predominant irritable bowel syndrome.
    Di Stefano M, Miceli E, Mazzocchi S, Tana P, Missanelli A, Corazza GR.
    Am J Gastroenterol; 2007 Aug 15; 102(8):1720-6. PubMed ID: 17521397
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.